文献速递肿瘤 PET/CT核素与放射性配体治疗

PSMA PET/CT显像时的系统治疗反应评估标准提案:PSMA PET进展标准

Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria.
PubMed 文献 · J Nucl Med · 2019-12-05

文章指出约20%的前列腺癌患者在病程中出现转移,而现有PCWG2标准未纳入PSMA PET。作者基于PCWG2原则提出PSMA PET进展(PPP)标准,用3条标准定义PSMA治疗反应,以填补临床试验中分子影像进展定义的空白。

要点

  • PPP标准基于PCWG2原则,新增PSMA PET进展定义。
  • 出现≥2个新PSMA阳性远处病灶即可定义进展。
  • 1个新病灶或现有病灶增大/摄取增加≥30%需临床或活检/影像确认。

核心结论

  • 需要紧急建立PSMA PET的反应标准与进展标准,以定义前列腺癌疾病进展。
  • 作者提出的PPP标准在PCWG2原则基础上纳入PSMA PET标准。

研究设计与样本

  • 本文为提案性文章,旨在通过PSMA PET标准定义前列腺癌进展。
  • PPP提案基于与PCWG2标准相同的原则,并增加PSMA PET标准。

主要发现

  • 约20%的前列腺癌男性在病程中出现转移。
  • PCWG2标准包括临床、实验室参数及MRI、CT、骨扫描等常规影像,但不考虑PSMA PET。
  • PSMA PET不仅用于检测生化复发,还用于再分期和作为进行中临床试验的中间终点生物标志物。

关键数值与推荐

  • PPP标准一:出现2个或以上新的PSMA阳性远处病灶。
  • PPP标准二:出现1个新的PSMA阳性病灶, plus 一致的临床或实验室数据,并建议在PSMA PET后3个月内通过活检或相关影像确认。
  • PPP标准三:1个或多个现有病灶大小或PSMA摄取增加至少30%, plus 一致的临床或实验室数据,或在PSMA PET后3个月内通过活检或相关影像确认。

临床怎么用

  • 在临床试验中评估前列腺癌治疗有效性时,可参考PPP标准定义PSMA PET进展。
  • 应用PPP标准时需结合临床或实验室数据,必要时在3个月内进行活检或相关影像确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In around 20% of men with prostate cancer, metastasis develops during the course of their disease. Accordingly, discovering and developing new potent treatment strategies for patients with metastatic prostate cancer has been a major research focus during the last few decades. Identifying disease progression, especially within clinical trials, is essential in determining drug effectiveness. One major remaining question is how best to define disease progression. The criteria of the Prostate Cancer Clinical Trials Working Group (PCWG2) include clinical and laboratory parameters, as well as conventional imaging modalities such as MRI, CT, and bone scan findings, but advanced molecular imaging techniques, especially prostate-specific membrane antigen (PSMA) PET findings, are not considered. This is a problem because PSMA PET is used not only for detecting biochemical recurrence but also for restaging and as an intermediate-endpoint biomarker in ongoing clinical trials. Therefore, response criteria and PSMA PET progression (PPP) criteria need to be established with some urgency. The intent of this article is therefore to define prostate cancer progression by PSMA PET criteria. Our PPP proposal is based on the same principles as were applied for the PCGW2 criteria but adds value by including PSMA PET criteria. PPP defines PSMA treatment response using 3 different criteria. The first is the appearance of 2 or more new PSMA-positive distant lesions. The second is the appearance of 1 new PSMA-positive lesion plus consistent clinical or laboratory data and recommended confirmation by biopsy or correlative imaging within 3 mo of PSMA PET. The third is an increase in size or PSMA uptake of 1 or more existing lesions by at least 30%, plus consistent clinical or laboratory data or confirmation by biopsy or correlative imaging within 3 mo of PSMA PET.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Fanti S, Hadaschik B, Herrmann K, et al. Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria. J Nucl Med. 2019. PMID: 31806774. doi:10.2967/jnumed.119.233817

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。